Eight of nine patients with major pathological response (MPR) were alive and disease-free at five years, while six of 11 without MPR experienced relapse<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Feb. 15, 2023 (HealthDay News) — For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant nivolumab is associated with positive five-year outcomes, according to a study published online Feb. 15 in Clinical Cancer Research<\/em>.<\/p>\n Samuel Rosner, M.D., from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, and colleagues present five-year clinical outcomes from a first phase I\/II trial of neoadjuvant nivolumab in resectable NSCLC. Twenty-one patients with stage I to IIIA NSCLC were administered two doses of nivolumab for four weeks before surgery.<\/p>\n The researchers found that the five-year recurrence-free survival (RFS) and overall survival rates were 60 and 80 percent, respectively, with a median follow-up of 63 months. Trends toward favorable RFS were seen for the presence of major pathological response (MPR) and pretreatment tumor programmed death-ligand 1 positivity (hazard ratios, 0.61 [95 percent confidence interval, 0.15 to 2.44] and 0.36 [95 percent confidence interval, 0.07 to 1.85], respectively). Eight of nine patients with MPR were alive and disease-free at five-year follow-up; no cancer-related deaths were seen for those with MPR. However, six of 11 patients without MPR experienced relapse and three died.<\/p>\n “Neoadjuvant nivolumab monotherapy in NSCLC led to favorable long-term clinical outcomes, with a low rate of toxicity,” the authors write. “Clinicians should be confident in using immune checkpoint blockade in the preoperative setting.”<\/p>\n Several authors disclosed financial ties to pharmaceutical companies, including Bristol Myers Squibb, which manufactures nivolumab and partially funded the study.<\/p>\n